Clinical Report: FDA approves iberdomide for multiple myeloma
Overview
The FDA has granted accelerated approval for iberdomide in combination with daratumumab and dexamethasone for adults with multiple myeloma who have received at least one prior therapy. This approval is based on the phase 3 EXCALIBER-RRMM trial, which demonstrated a significant improvement in minimal residual disease-negative complete response rates, with 41% of patients achieving this outcome compared to 21% in the control group.
Background
Multiple myeloma is a hematologic malignancy characterized by the proliferation of abnormal plasma cells. Treatment options have evolved, but there remains a need for effective therapies for patients who have relapsed after prior treatments. The approval of iberdomide represents a new therapeutic option within the cereblon-modulating protein degrader class, which targets specific pathways involved in the disease.
Data Highlights
Outcome
ZDd (iberdomide group)
DVd (control group)
MRD-negative complete response
41%
21%
Serious adverse reactions
58%
N/A
Fatal adverse reactions
5%
N/A
Key Findings
Iberdomide is the first cereblon E3 ligase modulator approved by the FDA.
41% of patients receiving iberdomide, daratumumab, and dexamethasone achieved MRD-negative complete response.
Serious adverse reactions occurred in 58% of patients on the iberdomide regimen, including pneumonia and infections.
Fatal adverse reactions were reported in 5% of patients receiving iberdomide.
Common adverse reactions included neutropenia (90%) and infections (79%).
Clinical Implications
Clinicians should be aware of the potential for serious adverse reactions associated with iberdomide, including neutropenia and thromboembolic events, as reported in the trial data.
Conclusion
The approval of iberdomide provides a new option for treating relapsed or refractory multiple myeloma, with data from the EXCALIBER-RRMM trial indicating significant efficacy in achieving MRD-negative complete response.
Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.
National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.
